Brief Report: Phase IIa Safety Study of a Vaginal Ring Containing Dapivirine in Adolescent Young Women
- 1 February 2020
- journal article
- conference paper
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 83 (2) , 135-139
Abstract
Background: Young women aged 15–24 years are disproportionately affected by the HIV epidemic. Two phase III trials of a vaginal ring containing 25-mg dapivirine demonstrated HIV-1 risk reduction in adult women older than 21 years but not in those aged 18–21 years. Lack of protection was correlated with low adherence. Methods: In this phase-IIa, randomized, double-blind, placebo-controlled, US, multicenter trial of the dapivirine ring in sexually active females, aged 15–17 years, participants were randomized 3:1 to a dapivirine or placebo ring to be inserted monthly for 6 months (NCT02028338). Primary safety end points included grade 2 product related adverse events and any grade 3 and higher adverse events. Adherence to ring use was assessed by plasma dapivirine concentrations, residual levels in used rings, and self-report. A plasma dapivirine concentration of >95 pg/mL was used to define short-term adherence; a residual ring level of <23.5 mg was used to define long-term adherence. Acceptability was assessed through computer-assisted self-interviews. Results: Ninety-six participants were enrolled across 6 US sites. The median age was 16.0 years. There were no differences in safety outcomes between treatment arms. Adherence to the dapivirine ring was demonstrated by both plasma measurements (87%) and residual drug levels in rings (95%). Forty-two percent (95% confidence interval: 32 to 52) of participants reported that they never removed the ring. Participants noted no discomfort due to the ring at 87% of visits and “liking” the ring at 93% of visits. Conclusion: The dapivirine vaginal ring, a promising topical microbicide, was well tolerated and acceptable in young US adolescents.Keywords
This publication has 10 references indexed in Scilit:
- Pregnancy and Infant Outcomes Among Women Using the Dapivirine Vaginal Ring in Early PregnancyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2018
- Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in WomenNew England Journal of Medicine, 2016
- Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in WomenNew England Journal of Medicine, 2016
- Adolescent girls and young women: key populations for HIV epidemic controlJournal of the International AIDS Society, 2015
- Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trialAIDS Care, 2014
- Dual quantification of dapivirine and maraviroc in cervicovaginal secretions from ophthalmic tear strips and polyester-based swabs via liquid chromatographic–tandem mass spectrometric (LC–MS/MS) analysisJournal of Pharmaceutical and Biomedical Analysis, 2014
- A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy womenAIDS, 2014
- Disclosure of Microbicide Gel Use to Sexual Partners: Influence on Adherence in the CAPRISA 004 TrialAIDS and Behavior, 2014
- The Development and Validation of an UHPLC–MS/MS Method for The Rapid Quantification of The Antiretroviral Agent Dapivirine in Human PlasmaBioanalysis, 2013
- Youth-Specific Considerations in the Development of Preexposure Prophylaxis, Microbicide, and Vaccine Research TrialsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010